2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
25
Temozolomide
22
Vincristine
18
Irinotecan
18
Doxorubicin
13
Topotecan
10
Melphalan
10
Etoposide
10
Ifosfamide
8
Busulfan
8
cabozantinib
7
Magnetic Resonance Spectroscopy
7
Granulocyte Colony-Stimulating Factor
7
Filgrastim
6
regorafenib
5
fludarabine
5
X-Rays
5
Specimen Handling
5
Sirolimus
5
Radiotherapy
5
Gemcitabine
5
Drug Therapy
5
pegfilgrastim
4
palbociclib
4
liposomal doxorubicin
4
irinotecan sucrosofate
4
ganitumab
4
fludarabine phosphate
4
Trabectedin
4
Phantoms, Imaging
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled